Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00248_DB00315_nanopub.RAjdJ7VPLqNnYVqTzeOFomwyRKGUjnZx1A0HbIpEV5d50#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00248_DB00315 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00248_DB00315 label "DDI between Cabergoline and Zolmitriptan - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy. [drugbank_resource:DB00248_DB00315]" assertion.
- drugbank_resource:DB00248_DB00315 identifier "drugbank_resource:DB00248_DB00315" assertion.
- drugbank_resource:DB00248_DB00315 title "DDI between Cabergoline and Zolmitriptan - Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy." assertion.
- drugbank:DB00315 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00248_DB00315 assertion.
- drugbank:DB00248 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00248_DB00315 assertion.